Latest news with #NeOnc
Miami Herald
6 days ago
- Business
- Miami Herald
New to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
CALABASAS, CA AND ABU DHABI, UAE / ACCESS Newswire / August 11, 2025 / NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). This milestone marks the fulfillment of all contingencies required to finalize the previously announced $50 million cornerstone investment from Quazar Investment into NuroMENA Holdings Ltd. This strategic alliance will accelerate the launch of NeOnc's innovative CNS platform across the MENA region and fast-track development of its clinical programs, including NEO212 and NEO100, two advanced therapies with the potential to transform outcomes for brain cancer and other CNS conditions. Vince Caruso, CEO and Creator of New to The Street, added: About NuroMENA Holdings Ltd. NuroMENA is a UAE-based subsidiary of NeOnc Technologies Holdings, Inc., created to oversee regional clinical operations, partnerships, and innovation in the Middle East and North Africa. Upon closing of the $50 million investment and execution of the change of control, NuroMENA will be majority-controlled by Quazar Investment, with joint governance oversight and strategic alignment between NeOnc and Quazar to accelerate breakthrough CNS therapies across the region. NuroMENA was officially incorporated under ADGM on August 6, 2025. About NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) NeOnc Technologies is a multi-Phase 2 clinical-stage biotechnology company focused on novel therapies for brain cancer and other CNS disorders. With a robust intellectual property portfolio and strong academic collaborations, NeOnc is committed to transforming outcomes in one of the hardest-to-treat areas of oncology. About Quazar Investment Quazar Investment is a leading strategic investment firm headquartered in Abu Dhabi, managing over $3.3 billion in assets under management (AUM). Backed by key partnerships with the UAE Government, Quazar focuses on transformative investments in biotechnology, healthcare, and next-generation infrastructure across the MENA region and globally. About New to The Street (NTTS) New to The Street is one of the longest-running U.S. and international television brands, broadcasting sponsored programming weekly on Bloomberg and FOX Business networks, while leveraging one of the largest business YouTube channels with over 3.2 million subscribers. NTTS maintains an expansive social footprint with 711,000+ followers, friends, and connections across X, Facebook, LinkedIn, and Instagram. With over 16 years in business and more than 2,000 interviews broadcast, NTTS specializes in elevating corporate visibility through long-form interviews, targeted social media, and high-impact outdoor campaigns in Times Square and other iconic locations. Media Contact:info@ Investor Contact:James Carbonara - Hayden IR(646) 755-7412James@ Grace@ SOURCE: New To The Street
USA Today
31-07-2025
- Business
- USA Today
New to The Street Signs NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) to 12-Part National Broadcast Series Including T.V. Network Features, Earned Media, Commercials, and Iconic Outdoor Billboards
NEW YORK CITY, NEW YORK / ACCESS Newswire / July 30, 2025 / New to The Street, the nation's premier financial media platform for emerging public companies, proudly announces a major media partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI). Under this agreement, NeOnc will be featured in a 12-part national broadcast series, with exclusive monthly interviews airing on Bloomberg Television and Fox Business Network. The series will also include earned media distribution, commercial rotation across national networks, and outdoor billboard campaigns in the most visible financial corridors in the U.S. This partnership launches at a pivotal time for NeOnc Technologies, following two significant corporate milestones: The signing of a Letter of Intent to acquire breakthrough intellectual property (IP) for brain cancer treatment , positioning the company at the forefront of neuro-oncology innovation; The execution of a $50 million definitive strategic partnership with Quazar Investment, accelerating NeOnc's operational and clinical development roadmap. Breakthrough Science Meets Breakthrough Exposure The integrated media campaign includes: 12 Long-Form Network Broadcast Interviews from the Nasdaq and NYSE studios on Bloomberg TV and Fox Business as sponsored programming. More than 300 Monthly Commercial Spots across targeted investor and innovation-focused time blocks. Earned Media Coverage on major U.S. networks via NewsOut™, including CBS, NBC, and ABC affiliates. Iconic Billboard Placements in Times Square (Nasdaq Tower and Reuters Boards), NYC Financial District shelters, and premium taxi tops. Digital Amplification via YouTube and social platforms: New to The Street TV Channel : NewsOut Channel : Executive Commentary 'NeOnc is entering a new era, not only in terms of medical science but also visibility in the public markets. Their latest IP acquisition and $50 million partnership with Quazar reflect serious momentum,' said Vince Caruso, Founder and CEO of New to The Street. 'We're proud to provide a media platform that matches their global ambitions and innovations with real-world distribution, every month.' About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's lead therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California, consisting of issued patents and pending applications related to NEO100, NEO212, and other candidates from the NeOnc patent family for multiple uses, including oncological and neurological conditions. To learn more, visit About New to The Street Since 2009, New to The Street has been a leading force in financial media, showcasing public and private companies through its unmatched mix of national television broadcasts, digital syndication, and social media reach. With over 3.2 million subscribers on the New to The Street TV YouTube channel and a combined following of more than 511,000 across LinkedIn, Facebook, Instagram, and X, the platform delivers consistent visibility to investors, industry leaders, and the general public. New to The Street offers more linear 'real TV' broadcast distribution than any other outlet in the space, with long-running placements across Bloomberg TV, Fox Business Network, and other national platforms. Its 'Opportunities to Consider™' segments and in-depth executive interviews have become a trusted source for market-moving narratives, emerging growth stories, and thought leadership across finance, tech, biotech, and beyond. Learn more: Media Contact: Monica Brennan Head of Communications, New to The Street Monica@ SOURCE: New To The Street View the original press release on ACCESS Newswire
Yahoo
06-06-2025
- Business
- Yahoo
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational research, and academic medicine. Dr. Neman joins NeOnc Technologies Holdings Inc. (NeOnc) from the Keck School of Medicine at the University of Southern California (USC), where he serves as Associate Professor of Neurological Surgery and Physiology & Neuroscience, and Scientific Director of the USC Brain Tumor Center. At USC, he also leads the Cancer Biology and Genomics PhD Program and serves as Director of Cancer Research Training and Education Coordination at the USC Norris Comprehensive Cancer Center- a leading National Cancer Institute-designated cancer research hospital. A nationally recognized leader in neurooncological sciences and cancer neuroscience, Dr. Neman's research has advanced the understanding of how brain microenvironments influence the progression of brain tumors and metastases. His pioneering studies on tumor-neuron interactions, GABAergic signaling in cancer, and mechanisms of leptomeningeal dissemination have helped shape new therapeutic paradigms for both adult and pediatric brain tumors. 'I am deeply honored to join NeOnc at this exciting time,' said Dr. Neman. 'NeOnc's commitment to developing innovative therapeutics, including Blood Brain Barrier-penetrant compounds like NEO212 and NEO100, aligns perfectly with my lifelong passion to improve outcomes for patients with brain tumors. I look forward to helping lead the translation of promising discoveries from the lab into meaningful clinical impact.' In his role as Chief Clinical Officer, Dr. Neman will lead NeOnc's clinical development strategy, including investigator-initiated trials and precision oncology partnerships. He will also play a key role in expanding NeOnc's research collaborations with academic institutions, regulatory agencies, and patient advocacy groups. 'Dr. Neman's appointment signals a major step forward in NeOnc's mission to transform the treatment landscape for patients with life-threatening cancers with poor outcomes,' said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, Inc. 'His academic and clinical leadership, coupled with his deep expertise in brain tumor biology, will be instrumental in accelerating all four of our clinical trials—especially our lead asset, NEO100, which is approaching the completion of its Phase 2a trial with full enrollment achieved ahead of schedule. As we look to add AI and quantum computing into our expanding platform in drug delivery and bio-conjugation, Dr. Neman's appointment further strengthens our commitment to advancing precision therapies and driving toward FDA approval.' About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): NeOnc Technologies is a publicly traded, clinical-stage biopharmaceutical company developing innovative therapies for brain and central nervous system cancers. Its lead programs—NEO100-01, NEO100-02, NEO100-03, and NEO212—utilize proprietary formulations to bypass the blood-brain barrier and target malignancies with precision. The company's IP portfolio includes 176 patents worldwide, reflecting a broad platform with strong commercialization potential. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward-Looking Statements All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law. 'NEO100' is a registered trademark of NeOnc Technologies Holdings, Inc. Company Contact:23975 Sorrento Park Suite 205, Calabasas, CA, 91302info@ Investor Relations:James CarbonaraHayden IR369 Lexington AvenueSecond FloorNew York, NY 10017Office: (646)-755-7412James@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-04-2025
- Business
- Yahoo
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
-- 176 Patents Issued and Outstanding Reinforces NeOnc's Competitive Position -- CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company's IP portfolio, covering its core pipeline, currently comprises 126 issued patents - 29 in the United States and 97 internationally; and 50 pending patents - 19 in the United States and 31 internationally. NeOnc's expanding IP portfolio reflects its innovation engine as well as its commitment to protecting and maximizing the commercial potential of its therapeutic candidates, globally. The Company's IP protections span all major pharmaceutical markets, including the U.S., European Union, China, Japan, Brazil, and Australia, as the Company advances its portfolio of next-generation therapeutics toward regulatory approval. 'Intellectual property is a cornerstone of our strategy, and the strength of our global patent portfolio reflects the depth of our innovation and the breadth of our ambition,' said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. 'This portfolio enhances our ability to protect our breakthroughs in oncology and neurology, including our intranasal drug delivery platform, and safeguards our proprietary capability to bio-conjugate existing standard-of-care treatments like TMZ. Together, these protections ensure a strong foundation for long-term value creation for shareholders and life-changing solutions for patients.' NeOnc's lead programs — including NEO100, NEO212, NEO214, and NEO400 — are protected by extensive patent coverage, notably: NEO100, ultrapure perillyl alcohol, which is covered by eight U.S. patents expiring between 2031 and 2036, with potential extensions via the FDA's patent term extension program and additional exclusivity through NEO100's Orphan Drug Designation. NEO212 and NEO214, structurally unique perillyl alcohol conjugates, which benefit from Orange Book eligibility and new chemical entity data exclusivity provisions post-approval. NEO400, a topical anticancer agent, that recently has secured broad patent coverage in Europe, with similar filings underway globally. Additionally, the Company holds key patents for the use of its compounds in permeabilizing the blood-brain barrier, with protections extending into 2039. 'Our mission is to bring paradigm-shifting therapies to patients with some of the most challenging conditions, and our growing patent estate gives us the platform to do just that,' said Dr. Thomas Chen, CEO of NeOnc Technologies. 'We will continue to invest aggressively in IP as we advance toward clinical and regulatory milestones across our pipeline.' ABOUT NEONC TECHNOLOGIES HOLDINGS, Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward Looking Statements All statements other than statements of historical facts included in this press release are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as 'projected,' 'expect,' 'possibility' and 'anticipate,' or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law. 'NEO100' is a registered trademark of NeOnc Technologies Holdings, Inc. Company Contact: Patrick WaltersChief Operations OfficerNeOnc Technologies Holdings, Inc. info@ Investor Relations: Roger Pondel / Laurie BermanPondelWilkinson Inc.(310) 279-5980rpondel@ in to access your portfolio
Bahrain News Gazette
10-04-2025
- Business
- Bahrain News Gazette
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) , a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company's strategic and clinical initiatives. 'Amir's appointment as President reflects our commitment to strong, visionary leadership as NeOnc advances its clinical programs,' said Dr. Thomas Chen, CEO of NeOnc. 'His extensive experience in building and scaling companies, coupled with his deep understanding of capital markets and business development, will be instrumental as we move forward.' Heshmatpour brings over 25 years of senior executive and board-level experience in business development, operations, finance, and M&A. He is the founder, chairman, and managing director of AFH Holdings & Advisory, where he has led IPO transactions totaling over $1.5 billion, and private funding and M&A transactions exceeding $5 billion in aggregate value. Previously, Heshmatpour served as Chairman and CEO of Metrophone Telecommunications, which he founded in 1994. Under his leadership, Metrophone completed 17 acquisitions and grew annual revenues to over $100 million during a decade of sustained expansion. He has served on the board of the UCLA Anderson School of Management for more than 12 years, and is a board member of the Make-A-Wish Foundation for the Central Coast and Southern Central Valley of California. 'I'm honored to step into the role of President at such a pivotal time in NeOnc's evolution. By formalizing my day-to-day oversight of Company operations, we're enabling Dr. Chen to focus fully on driving our clinical trials forward, with a specific emphasis on patient enrollment for our lead drug candidates — NEO212, our TMZ bio-conjugate, and NEO100,' said Heshmatpour. 'With our promising drug candidates advancing through clinical development, I'm confident in our ability to deliver significant value to patients, providers, and shareholders alike.' ABOUT NEONC TECHNOLOGIES HOLDINGS, INC. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100 and NEO212 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit . Important Cautions Regarding Forward Looking Statements All statements other than statements of historical facts included in this press release are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as 'projected,' 'expect,' 'possibility' and 'anticipate,' or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law. 'NEO100' is a registered trademark of NeOnc Technologies Holdings, Inc. Company Contact: Patrick Walters Chief Operations Officer NeOnc Technologies Holdings, Inc. [email protected] Investor Relations: Roger Pondel / Laurie Berman PondelWilkinson Inc. (310) 279-5980 [email protected] / [email protected] GlobeNewswire Distribution ID 9419859
